MICHELLE PALACIOS,ERIC J. GAUKEL,STEPHEN A. WRING,MAGDALENA ALONSO-GALICIA
申请号：
US16777458
公开号：
US20200237759A1
申请日:
2020.01.30
申请国别(地区):
US
年份:
2020
代理人:
摘要：
There is provided a daily dosage regimen for treating pulmonary arterial hypertension. The regimen takes the form of two discrete dosage forms. Each dosage form includes an amount of about 600 mg to about 800 mg of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′；-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate. There is also another method for providing a daily dosage regimen. There is also provided several methods for treating pulmonary arterial hypertension. There is provided a method for reducing the level of serotonin biosynthesis by at least 50%. There is also provided a method for achieving an AUC0-tau of ≥；2530 ng·hr/mL of (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′；-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid. There is provided a method of achieving a >；50% reduction in urinary 5-HIAA.
